INSPIRE Turkey

Withdrawn

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

A Retrospective, Multi-centre, Non-interventional Study Investigating the Clinical Parameters Associated With Saxenda® Use and Discontinuation in Patients in Turkey. INSPIRE Turkey (INvestigate the Impact of Saxenda® on Patient's Weight In a REal World Setting in Turkey) Study

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

—

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05438186

Org study IDNN8022-4805

Secondary IDU1111-1259-8749World Health Organization (WHO)

Timeline

Milestones

Study first posted2022-06-29actual

Study start2022-09-01estimated

Primary completion2022-09-30estimated

Study completion2022-10-31estimated

Last update posted2023-01-25actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Participants with obesity who received initial prescription of Saxenda® and maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription for weight management.

Inclusion criteria

•Patients who have signed consent before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

•Patients who have polyclinic visits between 01 June 2022 and 31 October 2022 and who have received initial prescription of Saxenda® for weight management at least 52 weeks prior to study enrolment.

•Patients who have maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription.

•Patients who have 12-month follow-up data, even if discontinued Saxenda ® treatment.

•Patients who have body weight measurement at baseline and at least 1 more body weight measurement following the Saxenda® prescription

•Age greater than or equal 18 years at the time of signing informed consent

Exclusion criteria

•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

•Patient charts lacking any follow-up information for at least 16 weeks.

•Patients who have been treated with anti-obesity medication for last 12 weeks prior to initiation of Saxenda® treatment.

•Patients who receive GLP-1 receptor agonist for treatment of Type 2 diabetes.

•Patients who have undergone bariatric surgery or use of minimal-invasive weight loss devices (i.e. intragastric balloons, lap bands) within 1 year before starting Saxenda® treatment.

Endpoints (15)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Safety / tolerability / PK

Weight & body composition

9 endpoints

Primary/protocol endpoint

Relative change in body weight

Time frame:At 52th week after treatment initiation

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of relative change in body weight

Time frame:At 16th week after treatment initiation

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of relative change in body weight

Time frame:At 26th week after treatment initiation

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute body weight change

Time frame:At 16th week after treatment initiation

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Absolute body weight change

Time frame:At 26th week after treatment initiation

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Absolute body weight change

Time frame:At 52th week after treatment initiation

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Achievement of greater than or equal to 5% weight loss

Time frame:At 52th week after treatment initiation

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Achievement of greater than or equal to 10% weight loss

Time frame:At 52th week after treatment initiation

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Achievement of greater than or equal to 5% and greater than or equal to 10% weight loss

Time frame:At 26th week after treatment initiation

≥5% weight-loss responders

threshold achievement, improvement

Safety / tolerability / PK

6 endpoints

Secondary/protocol endpoint

Mean dose of Saxenda®

Time frame:At 16th week after treatment initiation

descriptive

Secondary/protocol endpoint

Mean dose of Saxenda®

Time frame:At 26th week after treatment initiation

descriptive

Secondary/protocol endpoint

Mean dose of Saxenda®

Time frame:At 52nd week after treatment initiation

descriptive

Secondary/protocol endpoint

Participants who have discontinued Saxenda®

Time frame:At 16th week after treatment initiation

Discontinuation due to AE

threshold achievement, event

Secondary/protocol endpoint

Participants who have discontinued Saxenda®

Time frame:At 26th week after treatment initiation

Discontinuation due to AE

threshold achievement, event

Secondary/protocol endpoint

Participants who have discontinued Saxenda®

Time frame:At 52nd week after treatment initiation

Discontinuation due to AE

threshold achievement, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.